Published: November 2025 | Last updated: May 2026
PEP and PrEP are both HIV prevention medications, but they answer two very different questions. PEP is the emergency option, started within 72 hours after a possible exposure. PrEP is the planned option, taken daily or on demand to keep risk low before exposure happens. Confusing the two has real consequences: miss the 72-hour PEP window and there is no second chance for that specific exposure event.
This guide walks through what each medication does, when each one fits, how to get them, and what to do if you have already missed the PEP clock. The information here reflects current CDC and NIH guidance for HIV prevention in the United States.
One letter apart, very different jobs
PEP and PrEP sit one letter apart in spelling and a world apart in purpose. PEP stands for post-exposure prophylaxis. PrEP stands for pre-exposure prophylaxis. Both rely on antiretroviral medications, but the timing window and the use case are completely different.
PEP is what you reach for after something has already happened: a condom broke during sex with a partner whose HIV status is positive or unknown, you shared injection equipment, or you experienced sexual assault. The 72-hour clock starts from the exposure event, and earlier is dramatically better. Inside the first 24 hours is ideal.
PrEP is for the times before any specific exposure. People take PrEP because they expect to keep encountering some HIV risk, whether that means a partner whose status they cannot always confirm, ongoing dating, sex work, injection drug use, or being in a serodifferent relationship with someone whose viral load is not yet undetectable. The medication builds up in body tissues over days, then quietly does its job in the background.
If you remember nothing else from this article, remember this: PEP is a 72-hour emergency, PrEP is a daily or near-daily plan, and mistaking one for the other is the single most common reason people miss the chance to prevent an infection.
What PEP is, and when it applies
PEP is a 28-day course of antiretroviral medication that blocks HIV from establishing itself after exposure. The standard regimen in the United States is a combination of emtricitabine, tenofovir, and a third drug such as dolutegravir or raltegravir, prescribed for one month per the CDC's PEP guidance.
The hard rule: the first dose must be taken within 72 hours of the possible exposure. Sooner is dramatically better. PEP started within 2 hours of exposure is far more effective than PEP started at hour 70. After 72 hours, the medication can no longer reliably keep the virus from taking hold in cells that may already be infected.
PEP is intended for specific, identifiable exposures, not for repeated or ongoing risk. Common situations where clinicians prescribe PEP include:
- Unprotected receptive anal or vaginal sex with a partner whose HIV status is positive or unknown
- A condom break or slippage during sex with a partner of unknown or positive status
- Sharing needles, syringes, or other injection equipment
- Sexual assault
- Occupational exposures, such as needlestick injuries in healthcare or research
If a possible exposure happened in the last three days, treat it like a time-sensitive medical event. Call an emergency room, an urgent care center, or a sexual health clinic that prescribes PEP and ask to be evaluated immediately. Telehealth platforms can sometimes prescribe same-day PEP when no in-person provider is reachable.
| Scenario | Is PEP Recommended? | Time Since Exposure |
|---|---|---|
| Condom broke during sex with HIV-positive partner | Yes | Within 72 hours |
| Unprotected sex with partner of unknown status | Often yes (risk assessment needed) | Within 72 hours |
| Needle sharing with someone living with HIV | Yes | Within 72 hours |
| Sexual assault with possible HIV exposure | Yes, seek emergency care | Immediately |
| Consensual sex more than 3 days ago | No, PEP is no longer effective | Outside 72-hour window |
What PrEP is, and who it is for
PrEP is taken before any HIV exposure to keep the risk of infection low while you continue with your normal life. Two oral medications are FDA-approved for daily PrEP in the United States: emtricitabine with tenofovir disoproxil fumarate (Truvada), and emtricitabine with tenofovir alafenamide (Descovy). A long-acting injectable called cabotegravir (Apretude) is also approved, given every two months after a short lead-in period.
When taken as prescribed, daily oral PrEP reduces the risk of getting HIV from sex by about 99% according to NIH HIVinfo. For people who inject drugs, consistent use reduces the risk of getting HIV from injection drug use by at least 74%. Skipped doses chip away at this protection.
PrEP is for anyone who anticipates ongoing HIV risk, full stop. The persistent myth that PrEP belongs only to one demographic has caused real harm. Cisgender women, transgender people, straight men, and serodifferent couples have all been told at clinics that PrEP is somehow not for them. The clinical reality is the opposite. PrEP is appropriate for sexually active people of any gender or orientation who want a buffer against partners whose status they cannot guarantee, for people who use injection drugs, and for people in serodifferent relationships where the partner with HIV is not yet on suppressive treatment.
If you anticipate the same kind of situation that just had you searching for PEP, that is a clear signal PrEP is worth a conversation with a provider.
PEP vs PrEP, side-by-side
The simplest way to keep the two straight is to compare when each one is used, how long the course lasts, and what kind of access the medication requires. The table below sums it up.
| Factor | PEP | PrEP |
|---|---|---|
| When it is taken | After a possible HIV exposure | Before any HIV exposure |
| Timing matters? | Yes, must start within 72 hours | Yes, needs days to build up in tissues |
| How long do you take it? | 28 days (one-time course) | Daily or event-based, long-term |
| Who it is for | Anyone with a specific recent high-risk exposure | Anyone with ongoing or anticipated HIV risk |
| Where to get it | ER, urgent care, sexual health clinics, rapid telehealth | Primary care, sexual health clinics, telehealth |
Do I need PEP or PrEP right now?
If a possible HIV exposure happened in the last 72 hours, you need PEP, and you need it today. If your risk is ongoing or anticipated, talk to a provider about PrEP. If your exposure was more than three days ago, PEP is no longer an option, but testing at the right window and starting PrEP for future protection both still make sense.
How fast does each one start working?
PEP starts working at the first dose. The medication needs to reach cells throughout the body before HIV has time to establish a stable infection, which is why the 72-hour cap exists. Inside that window, the immune system and the drug together have a real chance to clear the exposure. After it, the virus has often already replicated past the point where antiretroviral prophylaxis can intervene. The CDC's clinical PEP guidance treats the 72-hour mark as a hard cutoff for routine PEP initiation.
PrEP takes longer to reach full protection because the drug has to build up in the tissues where exposure can happen. CDC clinician guidance currently estimates that daily oral PrEP reaches maximum protection at about 7 days for receptive anal sex, and at about 21 days for receptive vaginal sex, injection drug use, and other exposure routes. This is not a single switch that flips on overnight. It is a steady buildup.
Some cisgender men who have sex with men use on-demand or event-based dosing, often called the 2-1-1 schedule: two pills 2 to 24 hours before sex, one pill 24 hours after the first dose, then one pill 48 hours after. The 2-1-1 approach is not currently recommended for cisgender women, transgender people, or anyone whose anticipated exposure is through vaginal sex or injection drug use, because the supporting pharmacokinetic data are specific to anal exposure.
The practical takeaway: do not start daily PrEP the morning before a high-risk encounter and expect to be protected by evening. Build the shield first, then count on it.
Side effects, and what to actually expect
Both PEP and PrEP use medications that have been used to treat HIV for years, so the safety profile is well established. Side effects happen, and they look a little different between the two.
PEP tends to feel rougher in the first week. People commonly report nausea, fatigue, headache, and sometimes diarrhea as the body adjusts to the three-drug regimen. These symptoms usually settle by the second week and resolve once the 28 days are over. Eating with the dose, staying hydrated, and pre-arranging a low-stress week one all help. Powering through, even when it feels like a stomach bug, is the point. An unfinished PEP course offers much less protection than a completed one.
PrEP tends to be milder. The first week or two on daily oral PrEP can come with mild stomach upset, sometimes called start-up syndrome, which usually fades. The known long-term concerns are small reductions in kidney function and bone mineral density, which is why people on long-term oral PrEP get kidney function tests, HIV tests, and renewed prescriptions every three months. The newer tenofovir alafenamide formulation and the injectable cabotegravir have different long-term profiles, and a provider can match the option to your kidney health, bone history, and lifestyle.
Neither medication is risk-free. Both are far safer than living with an untreated HIV infection.
PEP (28-day course): nausea, fatigue, headache, sometimes diarrhea in the first 1 to 2 weeks, fading as the body adjusts. Symptoms resolve when the course ends. The clinical priority is finishing all 28 days, even on the harder days.
PrEP (ongoing): mild stomach upset (start-up syndrome) in the first 1 to 2 weeks, then usually nothing day-to-day. Long-term oral PrEP includes routine three-month labs for kidney function and HIV status. The injectable formulation skips daily pills but trades them for a clinic visit every two months.
From PEP to PrEP, the natural transition
If you needed PEP, you had a reason. For many people, that reason does not vanish at the end of the 28-day course. The transition from PEP to PrEP is the standard clinical playbook for people whose risk is likely to repeat.
The handoff is straightforward. As you near the end of the PEP course, your prescribing clinician will order an HIV test. If the test is negative, daily PrEP can start immediately, with no gap in protection, because PrEP and PEP regimens share active drugs and starting PrEP directly as PEP ends means there is no unprotected interval between the two courses. Some clinicians prefer to retest at 4 to 6 weeks after PEP for additional confidence; oral PrEP can usually continue through that recheck window.
The risk to avoid here is the gap. People sometimes finish PEP, breathe out, and stop thinking about HIV prevention. Then a few weeks later, the same kind of situation that prompted PEP happens again, and they are unprotected.
What if the 72-hour window has already closed?
When more than three days have passed since the possible exposure, PEP is no longer on the table. This is hard news, especially when the panic has only just started to set in. The clinical path forward shifts from prevention to testing.
Modern HIV tests detect infection at different timelines:
- Fourth-generation laboratory antigen-antibody tests detect most infections by 18 to 45 days after exposure.
- Rapid antibody tests detect most infections by 23 to 90 days, with the median around 35 days.
- Nucleic acid tests (NAT) can detect the virus itself within 10 to 33 days, but are reserved for specific clinical situations.
Testing at the appropriate window gives you a real answer. Testing too early gives a false sense of security. If your possible exposure was a week ago, a same-day test will not yet tell you anything reliable; mark the calendar for the 4-to-6 week point for a lab antigen-antibody test, and again at 90 days for full clearance with most rapid tests.
PrEP becomes the question for the next exposure, not this one. Starting PrEP after a missed PEP window cannot undo the exposure that already happened, but it can prevent the next one. Many people whose first encounter with HIV prevention is a panicked search for PEP end up on PrEP afterward, precisely because they do not want the same panic again.
Cost, access, and getting the right one fast
PEP and PrEP follow different access paths and different cost structures.
PEP is treated as emergency medication in the United States. Most insurance plans cover PEP under emergency or preventive care. If you are uninsured, the manufacturer of the most common PEP regimen runs a free PEP medication program for eligible patients, and many state and local health departments have rapid-access PEP funds. The harder problem is usually finding a provider in time. Hospital emergency rooms, urgent care, sexual health clinics, and a growing number of telehealth platforms can prescribe PEP same-day. If the first place you call does not seem familiar with PEP, call another. The 72-hour clock does not pause while you search.
PrEP access is steadier but takes a bit of setup. Daily oral PrEP is available through primary care physicians, sexual health clinics, and several telehealth platforms that ship to your door. Under the Affordable Care Act, most private insurance and Medicaid plans must cover PrEP, the associated clinic visits, and the lab work at no cost-share as preventive care. If you are uninsured, the federal Ready, Set, PrEP program provides PrEP medication at no cost for people who qualify, and the drug manufacturers also run patient assistance programs.
The injectable formulation requires a clinic visit every two months for the maintenance dose, and it is worth confirming exact coverage with your provider and your plan before committing.
If you need PEP today: a hospital emergency room is the most reliable single point of access in the United States, and overnight or weekend access usually goes through the ER. Urgent care clinics and dedicated sexual health clinics are next. Telehealth platforms that advertise same-day PEP prescriptions are increasingly an option when no local clinic is reachable.
If you need PrEP this month: primary care, a sexual health clinic, or a PrEP-focused telehealth service are all reasonable starting points. Under the Affordable Care Act, most private insurance and Medicaid plans must cover PrEP medication, clinic visits, and lab work at zero cost-share as preventive care. The federal Ready, Set, PrEP program covers medication for people who qualify and are uninsured.
Stigma, access, and who gets missed
HIV prevention is a YMYL category in more ways than one. There is real evidence that people outside the most-marketed PrEP demographics, including cisgender women, transgender people, and Black and Latino communities, are under-prescribed relative to their actual HIV incidence. A provider who tells you PrEP is not for you because of your gender, race, or relationship status is working from outdated assumptions, not from current clinical evidence.
The CDC and most national medical organizations recommend offering PrEP to anyone whose sexual or injection-related history points to substantial HIV risk, without limiting that recommendation to specific demographic groups. If you have asked about PrEP and been brushed off, it is reasonable to ask again, request a referral to a sexual health specialist, or use a telehealth platform that prescribes PrEP without gatekeeping.
The same applies to PEP. Anyone with a qualifying exposure in the last 72 hours should be able to access PEP, period. If you are told you do not fit the profile, ask what exposure criteria the provider is actually applying and request a referral if you do not get an answer that matches CDC guidance.
Quick decision tree, in plain English
Use the table below to pick your next concrete step based on the situation you are actually in right now. Money, time, geography, and provider bias all enter the picture, but the medical priority falls out cleanly from a single question: when did the possible exposure happen?
| Your situation | Next step | Timing |
|---|---|---|
| Possible exposure in the last 72 hours | Go for PEP through an ER, urgent care, sexual health clinic, or a rapid telehealth provider | Today, sooner is better |
| Possible exposure more than 72 hours ago | PEP can no longer help with this exposure. Plan HIV testing at the appropriate window and consider PrEP going forward | Test at 4-6 weeks, recheck at 90 days |
| Anticipating similar situations in the future | Discuss daily oral PrEP, on-demand 2-1-1 (cis men, anal exposure only), or the bi-monthly injection | Start before the next likely exposure |
| Partner has HIV with an undetectable viral load | U=U: sexual transmission risk is effectively zero. PrEP is optional for extra reassurance during early treatment or any treatment break | Confirm partner's viral load every 3-6 months |
| Unsure whether what happened counts as exposure | Get tested at the right window for clarity. A negative test gives certainty; a positive one routes you straight into treatment | Test at 4-6 weeks post-event |
PEP must be started as soon as possible after a possible HIV exposure, and always within 72 hours.
FAQs
- Can I take PEP and PrEP at the same time?
- No, they are not used simultaneously. PEP is a 28-day course after a specific exposure; PrEP is taken on an ongoing schedule. If you finish PEP and still have ongoing HIV risk, a prescriber can transition you directly onto PrEP once an HIV test confirms you remain negative, with no gap in protection.
- How quickly do I need to start PEP after exposure?
- The hard cap is 72 hours from the exposure, and earlier is dramatically better. PEP started within 2 to 4 hours is more effective than PEP started at hour 70. If you think you might qualify, call an ER, urgent care, or sexual health clinic immediately, even at night or on a weekend.
- How long until PrEP fully protects me?
- The timeline depends on which tissue is being protected. For receptive anal sex, drug levels reach peak protection in roughly a week. For vaginal sex, injection drug use, and other routes, allow closer to three weeks. Starting PrEP days before an anticipated exposure is not enough; the protection accumulates gradually, and a single early pill will not have you covered.
- What happens if I miss a PrEP dose?
- Occasional missed doses are not catastrophic, but consistent dosing is what keeps drug levels in tissue high enough to block HIV. If you skip several days in a row, ask your provider whether you need extra precautions or a top-up window before relying on PrEP again. The injectable formulation removes the daily-pill question entirely.
- Does PEP have side effects?
- Yes. The 28-day course commonly causes nausea, fatigue, and headache in the first week, sometimes with mild diarrhea. Symptoms usually settle as the body adjusts. Stopping early reduces PEP's effectiveness, so most providers help patients push through the rough first days.
- Can I get PEP from a regular pharmacy without a prescription?
- Not directly. PEP requires a prescription and a brief risk assessment. The fastest paths are an emergency room, urgent care, a sexual health clinic, or a telehealth platform that handles same-day PEP. The retail pharmacy then fills the script for you.
- Is PrEP only for gay men?
- No. PrEP is recommended for any sexually active person with substantial HIV risk, including cisgender women, transgender people, straight men, people in serodifferent relationships, and people who inject drugs. Early marketing focused on one demographic and that has caused real under-prescribing in other groups. If a provider tells you PrEP is not for you without asking about your actual risk, seek a second opinion.
- I already missed the 72-hour window. What now?
- PEP cannot help with that exposure. The next step is testing at the right window: roughly 18 to 45 days for a fourth-generation lab antigen-antibody test, longer for rapid antibody tests. While you wait, condoms or abstinence keep partners protected. If exposure is likely to repeat, talk to a provider about starting PrEP now so the next event is already covered.
Clarity is the protection you deserve
HIV prevention is a quiet modern success story most people never hear about. PEP works. PrEP works. Both have decades of clinical data behind them. The failure point is rarely the medicine; it is the system that does not tell people the two exist, or that gates access behind shame, assumption, or geography.
If you are reading this because something just happened, do not wait to call. If you are reading this because you want to plan ahead, that decision will likely matter more to your health over the next ten years than almost any other you make this year. Either way, the next step is small and concrete: pick up the phone, open a telehealth app, or place a test order to find out where you actually stand.
How We Sourced This Article: This guide synthesizes current CDC clinical guidance on PEP and PrEP, NIH HIVinfo fact sheets, and the World Health Organization's dedicated PEP guidelines, plus public clinical-provider supplements from the CDC HIV Nexus program. We do not provide individual medical advice. For a possible exposure within the last 72 hours, contact a clinician, emergency room, or sexual health clinic immediately.
- U.S. Centers for Disease Control and Prevention. Preventing HIV with PEP, including the 72-hour window and standard 28-day regimens.
- U.S. Centers for Disease Control and Prevention. Preventing HIV with PrEP. General overview of PrEP options and access.
- U.S. Centers for Disease Control and Prevention HIV Nexus. Clinical guidance for healthcare providers on post-exposure prophylaxis.
- NIH HIVinfo. Post-Exposure Prophylaxis (PEP) consumer fact sheet.
- NIH HIVinfo. Pre-Exposure Prophylaxis (PrEP) consumer fact sheet, source of the about-99% effectiveness figure for daily oral PrEP taken as prescribed.
- World Health Organization. Guidelines for HIV post-exposure prophylaxis (2024). WHO's dedicated PEP clinical guidance covering timing, recommended regimens, and special population considerations.
- World Health Organization. HIV topic page covering prevention, treatment, and global epidemiology.
